KOSELUGO Alexion Pharmaceuticals Australasia Pty Ltd

KOSELUGO (selumetinib sulfate) is for the treatment of adults and children (aged 2 years and older) with neurofibromatosis type 1, a genetic disorder that causes benign tumors to grow on nerve tissue, various skin changes, and a wide range of other symptoms. For KOSELUGO treatment, patients must also have plexiform neurofibromas, a type of tumour that affects nerves and cannot be removed surgically.